205 related articles for article (PubMed ID: 16328595)
1. Titration of serum p53 antibodies in patients with gastric cancer: a single-institute study of 40 patients.
Shimizu K; Ueda Y; Yamagishi H
Gastric Cancer; 2005; 8(4):214-9. PubMed ID: 16328595
[TBL] [Abstract][Full Text] [Related]
2. Clinical Significance of Serum p53 Antibody in the Early Detection and Poor Prognosis of Gastric Cancer.
Kunizaki M; Fukuda A; Wakata K; Tominaga T; Nonaka T; Miyazaki T; Matsumoto K; Sumida Y; Hidaka S; Yasutake T; Sawai T; Hamamoto R; Nanashima A; Nagayasu T
Anticancer Res; 2017 Apr; 37(4):1979-1984. PubMed ID: 28373470
[TBL] [Abstract][Full Text] [Related]
3. Detection of preoperative serum anti-p53 antibodies in gastric cancer.
Nakajima K; Suzuki T; Shimada H; Hayashi H; Takeda A; Ochiai T
Tumour Biol; 1999; 20(3):147-52. PubMed ID: 10213922
[TBL] [Abstract][Full Text] [Related]
4. Clinical Value of Serum p53 Antibody in the Diagnosis and Prognosis of Colorectal Cancer.
Kunizaki M; Sawai T; Takeshita H; Tominaga T; Hidaka S; To K; Miyazaki T; Hamamoto R; Nanashima A; Nagayasu T
Anticancer Res; 2016 Aug; 36(8):4171-5. PubMed ID: 27466527
[TBL] [Abstract][Full Text] [Related]
5. Serum p53 antibody: useful for detecting gastric cancer but not for predicting prognosis after surgery.
Oshima Y; Suzuki T; Yajima S; Nanami T; Shiratori F; Funahashi K; Shimada H
Surg Today; 2020 Nov; 50(11):1402-1408. PubMed ID: 32458231
[TBL] [Abstract][Full Text] [Related]
6. Serum anti-p53 antibody detection in carcinomas and the predictive values of serum p53 antibodies, carcino-embryonic antigen and carbohydrate antigen 12-5 in the neoadjuvant chemotherapy treatment for III stage non-small cell lung cancer patients.
Yu DH; Li JH; Wang YC; Xu JG; Pan PT; Wang L
Clin Chim Acta; 2011 May; 412(11-12):930-5. PubMed ID: 21277290
[TBL] [Abstract][Full Text] [Related]
7. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma.
Shimada H; Takeda A; Arima M; Okazumi S; Matsubara H; Nabeya Y; Funami Y; Hayashi H; Gunji Y; Suzuki T; Kobayashi S; Ochiai T
Cancer; 2000 Oct; 89(8):1677-83. PubMed ID: 11042560
[TBL] [Abstract][Full Text] [Related]
8. The detection of serum anti-p53 antibodies from patients with gastric carcinoma in China.
Qiu LL; Hua PY; Ye LL; Wang YC; Qiu T; Bao HZ; Wang L
Cancer Detect Prev; 2007; 31(1):45-9. PubMed ID: 17292563
[TBL] [Abstract][Full Text] [Related]
9. [Serum anti-p53 antibodies in gastric cancer patients].
Lawniczak M; Bielicki D; Sulzyc-Bielicka V; Marlicz K; Starzyńska T
Pol Merkur Lekarski; 2007 Sep; 23(135):192-5. PubMed ID: 18080693
[TBL] [Abstract][Full Text] [Related]
10. Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy.
Lechpammer M; Lukac J; Lechpammer S; Kovacević D; Loda M; Kusić Z
Int J Colorectal Dis; 2004 Mar; 19(2):114-20. PubMed ID: 14634775
[TBL] [Abstract][Full Text] [Related]
11. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients.
Lai CL; Tsai CM; Tsai TT; Kuo BI; Chang KT; Fu HT; Perng RP; Chen JY
Clin Cancer Res; 1998 Dec; 4(12):3025-30. PubMed ID: 9865916
[TBL] [Abstract][Full Text] [Related]
12. Clinico-pathological characteristics of colorectal cancer and serum anti-p53 antibodies.
Bielicki D; Karbowniczek M; Sulzyc-Bielicka V; Kładny J; Boer C; Marlicz K; Domagała W
Pol J Pathol; 1999; 50(2):77-81. PubMed ID: 10481530
[TBL] [Abstract][Full Text] [Related]
13. Serum p53 antibody as a potential tumor marker in extrahepatic cholangiocarcinoma.
Okada R; Shimada H; Otsuka Y; Tsuchiya M; Ishii J; Katagiri T; Maeda T; Kubota Y; Nemoto T; Kaneko H
Surg Today; 2017 Dec; 47(12):1492-1499. PubMed ID: 28508195
[TBL] [Abstract][Full Text] [Related]
14. Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade.
Wu CW; Lin YY; Chen GD; Chi CW; Carbone DP; Chen JY
Br J Cancer; 1999 May; 80(3-4):483-8. PubMed ID: 10408857
[TBL] [Abstract][Full Text] [Related]
15. Serum p53 antibodies in correlation to other biological parameters of breast cancer.
Sangrajrang S; Arpornwirat W; Cheirsilpa A; Thisuphakorn P; Kalalak A; Sornprom A; Soussi T
Cancer Detect Prev; 2003; 27(3):182-6. PubMed ID: 12787724
[TBL] [Abstract][Full Text] [Related]
16. Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group.
Shimada H; Ochiai T; Nomura F;
Cancer; 2003 Feb; 97(3):682-9. PubMed ID: 12548611
[TBL] [Abstract][Full Text] [Related]
17. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
Suzuki H; Akakura K; Igarashi T; Ueda T; Ito H; Watanabe M; Nomura F; Ochiai T; Shimada H
J Urol; 2004 Jan; 171(1):182-6. PubMed ID: 14665872
[TBL] [Abstract][Full Text] [Related]
18. Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA.
Ushigome M; Shimada H; Miura Y; Yoshida K; Kaneko T; Koda T; Nagashima Y; Suzuki T; Kagami S; Funahashi K
Int J Clin Oncol; 2020 Apr; 25(4):622-632. PubMed ID: 31820210
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
Sun Z; Zhang N
World J Surg Oncol; 2014 Dec; 12():397. PubMed ID: 25543664
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of Preoperative Serum Levels of Five Tumor Markers (Carcinoembryonic Antigen, CA19-9, Alpha-fetoprotein, CA72-4, and CA125) in Gastric Cancer.
Kim JH; Jun KH; Jung H; Park IS; Chin HM
Hepatogastroenterology; 2014 May; 61(131):863-9. PubMed ID: 26176088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
